Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients

Introduction BAX 855 is a pegylated full‐length recombinant factor VIII (rFVIII) with an extended half‐life, built on a licensed rFVIII (ADVATE®). BAX 855 demonstrated efficacy and safety in prophylaxis and the treatment of bleeding episodes in previously treated patients (PTPs) with severe haemophi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haemophilia : the official journal of the World Federation of Hemophilia 2016-07, Vol.22 (4), p.e251-e258
Hauptverfasser:	Brand, B., Gruppo, R., Wynn, T. T., Griskevicius, L., Lopez Fernandez, M. F., Chapman, M., Dvorak, T., Pavlova, B. G., Abbuehl, B. E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Neutralizing - blood Coagulants - chemistry Coagulants - pharmacokinetics Coagulants - therapeutic use extended half-life Factor VIII - genetics Factor VIII - metabolism Factor VIII - therapeutic use haemophilia A Half-Life Hemophilia A - blood Hemophilia A - drug therapy Hemorrhage - prevention & control Hemostasis Humans Male Middle Aged pegylated recombinant factor VIII Perioperative Care perioperative haemostasis Polyethylene Glycols - chemistry Recombinant Proteins - biosynthesis Recombinant Proteins - chemistry Recombinant Proteins - pharmacokinetics Recombinant Proteins - therapeutic use Surgical Procedures, Operative Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!